Expression Level of Valosin Containing Protein is Associated with Prognosis of Primary Orbital MALT Lymphoma

Zhu, W F; Li, Kang; Gao, Yaping; Huang, Yan; Dong, Jing; Liu, Yü; Xiao, Lan; Yang, Guang

doi:10.7314/apjcp.2013.14.11.6439

Cited by 9 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2). These findings were consistent with previous studies of VCP expression in colorectal carcinoma, prostate cancer, oropharyngeal cancer, and lymphoma in which high expression of VCP was correlated with a lower 5-year survival rate [9,11,31,32]. In addition, subgroup analysis illustrated that VCP-positive breast cancer patients had worse OS than VCP-negative patients in both TNM stage I/II and III (Fig.…”

Section: Discussionsupporting

confidence: 92%

High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma

et al. 2015

View full text Add to dashboard Cite

Valosin-containing protein (VCP) is one of the AAA-ATPase superfamily members. The correlation between elevated expression of VCP and progression, prognosis, and the metastatic potential has been identified in various tumor types. However, the clinical impact of VCP in breast carcinoma has not been investigated. In the current study, the expression of VCP in 421 breast tumors and adjacent normal breast tissues was examined to investigate the correlation between VCP expression and clinicopathological features in patients with breast carcinoma. We found that the expression of VCP correlated with the TNM stage, Ki67 labeling, and lymph node metastasis (LNM). The expression of VCP was increased significantly in the cytoplasm of cancer cells compared to normal mammary epithelial cells, which was associated with decreased overall survival rates of patients with breast carcinoma (P < 0.001). In conclusion, this study demonstrates significant correlation between the cytoplasmic expression of VCP and adverse prognosis in breast carcinoma, suggesting that VCP may serve as a prognostic biomarker in breast carcinoma.

show abstract

Section: Discussionsupporting

confidence: 92%

High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In human papillomavirus (HPV)‐negative oropharyngeal squamous cell carcinoma patients treated with surgery, VCP expression evaluated by immunohistochemistry indicated that this protein could be used as a prognostic marker, and VCP intensity was apparently uncorrelated with HPV status . Zhu et al recently investigated the correlation between VCP expression and primary orbital mucosa‐associated lymphoid tissue in lymphoma patients treated by curative resection; the results showed that high expression of VCP was significantly correlated with recurrence, enlarged tumor size, and reduced survival . The novelty of our analysis is that elevated expression of VCP was indicative of unfavorable survival in ESCC patients who received radiotherapy.…”

Section: Discussionmentioning

confidence: 87%

“…With respect to the high protein synthesis burden and possible aneuploidy in many kinds of tumor cells, the ERAD pathway has a central role in regulating cancer cell proliferation . Over the past few years, high expression of VCP has been described and found to correlate with disease outcomes in various cancer patients who received surgical resection . Recently, several VCP inhibitors have been developed .…”

Section: Introductionmentioning

confidence: 99%

Targeting valosin‐containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma

et al. 2019

View full text Add to dashboard Cite

Overcoming resistance to radiation is a great challenge in cancer therapy. Here, we highlight that targeting valosin‐containing protein (VCP) improves radiation sensitivity in esophageal squamous cell carcinoma (ESCC) cell lines and show the potential of using VCP as a prognosis marker in locally advanced ESCC treated with radiation therapy. Esophageal squamous cell carcinoma cell lines with high VCP expression were treated with VCP inhibitor combined with radiotherapy. Cell proliferation, colony formation, cell death, and endoplasmic reticulum (ER) stress signaling were evaluated. Moreover, patients with newly diagnosed locally advanced ESCC who were treated with radiotherapy were analyzed. Immunohistochemistry was used to detect the expression of VCP. The correlation between overall survival and VCP was investigated. Esophageal squamous cell carcinoma cells treated with VCP inhibitor and radiotherapy showed attenuated cell proliferation and colony formation and enhanced apoptosis. Further investigation showed this combined strategy activated the ER stress signaling involved in unfolded protein response, and inhibited the ER‐associated degradation (ERAD) pathway. Clinical analysis revealed a significant survival benefit in the low VCP expression group. Targeting VCP resulted in antitumor activity and enhanced the efficacy of radiation therapy in ESCC cells in vitro. Valosin‐containing protein is a promising and novel target. In patients with locally advanced ESCC who received radiotherapy, VCP can be considered as a useful prognostic indicator of overall survival. Valosin‐containing protein inhibitors could be developed for use as effective cancer therapies, in combination with radiation therapy.

show abstract

“…VCP inhibitors perturb intracellular amino acid levels, activated eukaryotic translation initiation factor 2α kinase 4 (EIF2AK4), and enhance cellular dependence on amino acid supplies, consistent with a failure of amino acid homeostasis [65]. Thus, depletion of VCP triggers cancer cell death in part through inadequate control of protein synthesis and amino acid metabolism, and allows it to have implications for the development of anti-cancer therapies [65, 66]. OPG's interaction with VCP in the context of invasive and inflammatory breast cancer opens up many interesting avenues to research the therapeutic implications.…”

Section: Opg and Its Binding Partners In Breast Cancer Cellsmentioning

confidence: 99%

Osteoprotegerin rich tumor microenvironment: implications in breast cancer

Goswami

Sharma-Walia

2016

Oncotarget

View full text Add to dashboard Cite

Osteoprotegerin (OPG) is a soluble decoy receptor for tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL). It belongs to the tumor necrosis factor receptor superfamily (TNFRSF). OPG was initially discovered to contribute to homeostasis of bone turnover due to its capability of binding to receptor activator of nuclear factor-kappaB (NF-kB). However, apart from bone turnover, OPG plays important and diverse role(s) in many biological functions. Besides having anti-osteoclastic activity, OPG is thought to exert a protective anti-apoptotic action in OPG-expressing tumors by overcoming the physiologic mechanism of tumor surveillance exerted by TRAIL. Along with inhibiting TRAIL induced apoptosis, it can induce proliferation by binding to various cell surface receptors and thus turning on the canonical cell survival and proliferative pathways. OPG also induces angiogenesis, one of the hallmarks of cancer, thus facilitating tumor growth. Recently, the understanding of OPG and its different roles has been augmented substantially. This review is aimed at providing a very informative overview as to how OPG affects cancer progression especially breast cancer.

show abstract

Expression Level of Valosin Containing Protein is Associated with Prognosis of Primary Orbital MALT Lymphoma

Cited by 9 publications

References 21 publications

High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma

High expression of valosin-containing protein predicts poor prognosis in patients with breast carcinoma

Targeting valosin‐containing protein enhances the efficacy of radiation therapy in esophageal squamous cell carcinoma

Osteoprotegerin rich tumor microenvironment: implications in breast cancer

Contact Info

Product

Resources

About